Baird Downgrades Illumina

Analyst Aaron Geist says he doesn't see additional catalysts for the gene expression product company for another one or two quarters

Baird downgrades gene expression product company Illumina Inc. (ILMN ) to neutral from outperform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.